NasdaqGS:CTMX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has CytomX Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CTMX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CTMX's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-10.5%

CTMX

1.8%

US Biotechs

2.3%

US Market


1 Year Return

-1.8%

CTMX

45.9%

US Biotechs

23.8%

US Market

Return vs Industry: CTMX underperformed the US Biotechs industry which returned 45.9% over the past year.

Return vs Market: CTMX underperformed the US Market which returned 23.8% over the past year.


Shareholder returns

CTMXIndustryMarket
7 Day-10.5%1.8%2.3%
30 Day-4.3%6.7%4.8%
90 Day7.1%26.1%16.7%
1 Year-1.8%-1.8%48.3%45.9%26.6%23.8%
3 Year-74.2%-74.2%23.3%16.6%45.0%35.4%
5 Year-55.2%-55.2%58.9%46.7%126.2%101.0%

Long-Term Price Volatility Vs. Market

How volatile is CytomX Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CytomX Therapeutics undervalued compared to its fair value and its price relative to the market?

6.83x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CTMX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CTMX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CTMX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CTMX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CTMX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CTMX is overvalued based on its PB Ratio (6.4x) compared to the US Biotechs industry average (4.4x).


Next Steps

Future Growth

How is CytomX Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-17.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CTMX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CTMX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CTMX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CTMX's revenue (3.9% per year) is forecast to grow slower than the US market (10.6% per year).

High Growth Revenue: CTMX's revenue (3.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CTMX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CytomX Therapeutics performed over the past 5 years?

-12.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CTMX is currently unprofitable.

Growing Profit Margin: CTMX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CTMX is unprofitable, and losses have increased over the past 5 years at a rate of 12.5% per year.

Accelerating Growth: Unable to compare CTMX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CTMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).


Return on Equity

High ROE: CTMX has a negative Return on Equity (-111.6%), as it is currently unprofitable.


Next Steps

Financial Health

How is CytomX Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CTMX's short term assets ($340.3M) exceed its short term liabilities ($102.0M).

Long Term Liabilities: CTMX's short term assets ($340.3M) exceed its long term liabilities ($225.1M).


Debt to Equity History and Analysis

Debt Level: CTMX is debt free.

Reducing Debt: CTMX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CTMX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CTMX has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 29.7% each year.


Next Steps

Dividend

What is CytomX Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CTMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CTMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTMX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTMX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTMX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Sean McCarthy (53 yo)

9.42yrs

Tenure

US$3,769,930

Compensation

Dr. Sean A. McCarthy, D.Phil., has been the Chief Executive Officer and President of CytomX Therapeutics, Inc. since August 2011 and has been its Chairman since December 31, 2018. Dr. McCarthy joined the C...


CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD3.77M) is above average for companies of similar size in the US market ($USD1.65M).

Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Sean McCarthy
Chairman9.42yrsUS$3.77m0.45%
$ 1.9m
Frederick Gluck
Co-Founder & Independent Director10.33yrsUS$136.50k1.15%
$ 4.9m
Lloyd Rowland
Senior VPno dataUS$1.10m0.026%
$ 109.6k
Amy Peterson
Executive VP & Chief Development Officer1.25yrsUS$3.72m0.0067%
$ 28.8k
Carlos Campoy
Senior VP & CFO0.83yrno data0.0067%
$ 28.8k
Chau Cheng
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Sridhar Viswanathan
Senior Vice President of Process Sciences & Manufacturing Operations3.25yrsno datano data
Danielle Olander
Senior Vice Presidentno datano datano data
Alison Joly
Senior Vice President of Program & Alliance Management3yrsno datano data
Leslie Robbins
Senior Vice President of Intellectual Property1.92yrsno datano data
Alison Hannah
Senior VP & Chief Medical Officer0.92yrno datano data
Marcia Belvin
Senior VP & Head of Research0.25yrno datano data

1.6yrs

Average Tenure

57yo

Average Age

Experienced Management: CTMX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Sean McCarthy
Chairman9.42yrsUS$3.77m0.45%
$ 1.9m
Frederick Gluck
Co-Founder & Independent Director10.33yrsUS$136.50k1.15%
$ 4.9m
Elaine Jones
Independent Director1.67yrsUS$256.71k0.00031%
$ 1.3k
Louis Weiner
Member of Scientific Advisory Boardno datano datano data
John Scarlett
Independent Director4.58yrsUS$139.62k0%
$ 0
James Meyers
Independent Director2.08yrsUS$128.12k0%
$ 0
Matthew Young
Lead Independent Director2.08yrsUS$163.87k0%
$ 0
Halley Gilbert
Independent Director0.75yrno datano data
W. Kavanaugh
Member of Scientific Advisory Board0.083yrUS$1.48m0.041%
$ 177.0k
Lisa Butterfield
Member of Scientific Advisory Board1yrno datano data
Charles Fuchs
Independent Director3.25yrsUS$127.12k0%
$ 0
Lisa Coussens
Member of Scientific Advisory Board1yrno datano data

2.1yrs

Average Tenure

61.5yo

Average Age

Experienced Board: CTMX's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.2%.


Top Shareholders

Company Information

CytomX Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CytomX Therapeutics, Inc.
  • Ticker: CTMX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$429.622m
  • Shares outstanding: 60.51m
  • Website: https://www.cytomx.com

Number of Employees


Location

  • CytomX Therapeutics, Inc.
  • 151 Oyster Point Boulevard
  • Suite 400
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTMXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2015
6C1DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2015

Biography

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody te...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/26 01:03
End of Day Share Price2021/01/25 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.